AVPR2 and renal carcinoma: Targeting the V2R with tolvaptan has been, therefore, proposed for the therapeutical treatment of the autosomal dominant polycystic kidney disease (ADPKD) and renal carcinoma (van Gastel and Torres, 2017; Sinha et al., 2020).